Beacon Therapeutics Limited
- Website
- https://www.beacontx.com/
- Membership category
- Corporate
188 York Way, Rolling Stock Yard, 2nd Floor, London, N7 9AS, United Kingdom
Beacon Therapeutics Limited at a glance
Beacon Therapeutics is a leading clinical-stage biotechnology company dedicated to saving and restoring sight for people living with rare and prevalent ocular diseases.
About Beacon Therapeutics Limited
At Beacon, our focus revolves around utilizing Adeno-associated virus (AAV) to deliver gene constructs that encode therapeutic proteins in order to address retinal disorders.
- Gene therapy is the process of modifying a patient’s cells by adding a functional copy of the genetic factors contributing to the retinal disease. The new functional copy allows a patient’s own body to produce proteins to treat or prevent the progression of the disease. A single treatment may provide long lasting benefits to patients.
- AAVs are safe small viruses that naturally infect humans. With a very mild immune response detected, there are currently no known diseases caused by natural AAV infection.
- In the context of gene therapy, the original AAV genome is substituted with an enhanced human therapeutic gene(s), and the AAV is subsequently engineered to serve as precise vehicles for delivering therapeutic genes to the retinal cells. This modification potentially augments its safety profile and therapeutic efficacy in patients
